

SEQUENCE LISTING

<110> Kagoshima University
 <120> Separation and purification of CCAP product using affinity column
 <130> 21F110-PCT
 <150> JP2019-193830
 <151> 2019-10-24
 <160> 72
 <170> PatentIn version 3.5
 <210> 1
 <211> 13
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> IgG-BP
 <220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
 AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha
 <400> 1
 Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr
 1 5 10
 <210> 2
 <211> 17
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> IgG-BP
 <220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
 AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 2

Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe
1 5 10 15

His

<210> 3

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 3

Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser
1 5 10

<210> 4

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 4

Gly Pro Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser Phe

1 5 10 15

His

<210> 5
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 5

Ser Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe
1 5 10 15

His

<210> 6
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K,C,D,E, R, 2-Aminosuberic acid, or Diaminopropionic acid

<400> 6

Gly Asp Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe
1 5 10 15

His

<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 7

Gly	Pro	Ser	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5				10					15		

His

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 8

Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Ser	Phe
1				5				10					15		

His

<210> 9
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 9

Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	His
1				5				10					15		

His

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 10

Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5				10					15		

Tyr

<210> 11
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 11

Ser	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

Tyr

<210> 12
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 12

Ser	Asp	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

Tyr

<210> 13
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 13

Arg	Gly	Asn	Cys	Ala	Tyr	His	Xaa	Gly	Gln	Leu	Val	Trp	Cys	Thr	Tyr
1				5				10					15		

His

<210> 14
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X is homocysteine

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> Xaa can be any naturally occurring amino acid

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> X is homocysteine

<400> 14

Gly	Xaa	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys	Thr	Xaa
1				5					10					15	

His

<210> 15
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgG-BP

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn, AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 15

Arg	Arg	Gly	Pro	Asp	Cys	Ala	Tyr	His	Xaa	Gly	Glu	Leu	Val	Trp	Cys
1				5					10					15	

Thr Phe His

<210> 16
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn, AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 16

Asp	Cys	Thr	Tyr	His	Xaa	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 17

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn, AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 17

Asp	Cys	Ala	Tyr	His	Xaa	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 18

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 18

Asp Cys Thr Tyr His Xaa Gly Glu Leu Val Trp Cys Thr
1 5 10

<210> 19

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 19

Asp Cys Ala Trp His Xaa Gly Glu Leu Val Trp Cys Thr
1 5 10

<210> 20

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 20

Asp Cys Thr Tyr Thr Xaa Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 21
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 21

Asp	Cys	Ala	Tyr	Thr	Xaa	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 22
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 22

Asp	Cys	Ser	Tyr	Thr	Xaa	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 23
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
 AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 23

Asp	Cys	Thr	Trp	Thr	Xaa	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 24
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgG-BP

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
 AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 24

Asp	Cys	Thr	Tyr	His	Xaa	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 25
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgG-BP

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
 AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 25

Asp Cys Thr Tyr Arg Xaa Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 26

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 26

Asp Cys Thr Tyr Ser Xaa Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 27

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 27

Asp Cys Thr Tyr Thr Xaa Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 28

<211> 13

<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 28

Asp Cys Thr Tyr Thr Xaa Gly Glu Leu Val Trp Cys Thr
1 5 10

<210> 29
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 29

Asp Cys Thr Tyr Thr Xaa Gly Arg Leu Val Trp Cys Thr
1 5 10

<210> 30
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>

<221> MISC_FEATURE
<222> (6)..(6)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 30

Asp Cys Thr Tyr Thr Xaa Gly Asp Leu Val Trp Cys Thr
1 5 10

<210> 31
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is K, C, D, E, R, V, F, L, 2-Aminosuberic acid, Dpr, Orn,
AcOrn, AcDab, Dab, Nle, Nva, Tle, Ala(t-Bu), or Cha

<400> 31

Asp Cys Thr Tyr Thr Xaa Gly Asn Leu Ile Trp Cys Thr
1 5 10

<210> 32
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 32

Asp Cys Ala Tyr His Arg Gly Glu Leu Val Trp Cys Thr
1 5 10

<210> 33
<211> 17
<212> PRT
<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 33

Gly	Pro	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 34

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 34

Arg	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Ser
1				5				10				

<210> 35

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 35

Gly	Pro	Arg	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Ser	Phe
1				5					10					15	

His

<210> 36

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 36

Ser	Pro	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 37

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 37

Gly	Asp	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 38

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 38

Gly	Pro	Ser	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

His

<210> 39
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 39

Gly	Pro	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Ser	Phe
1				5					10					15	

His

<210> 40
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 40

Gly	Pro	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	His
1				5					10					15	

His

<210> 41
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 41

Gly	Pro	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

Tyr

<210> 42
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 42

Ser	Pro	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

Tyr

<210> 43
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 43

Ser	Asp	Asp	Cys	Ala	Tyr	His	Arg	Gly	Glu	Leu	Val	Trp	Cys	Thr	Phe
1				5					10					15	

Tyr

<210> 44
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 44

Asp Cys Thr Tyr His Arg Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 45
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 45

Asp Cys Ala Tyr His Arg Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 46
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 46

Asp Cys Thr Tyr His Arg Gly Glu Leu Val Trp Cys Thr
1 5 10

<210> 47
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 47

Asp Cys Ala Trp His Arg Gly Glu Leu Val Trp Cys Thr
1 5 10

<210> 48
<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 48

Asp	Cys	Thr	Tyr	Thr	Asn	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 49

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 49

Asp	Cys	Ala	Tyr	Thr	Asn	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 50

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 50

Asp	Cys	Ser	Tyr	Thr	Asn	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 51

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 51

Asp	Cys	Thr	Trp	Thr	Asn	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 52
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 52

Asp Cys Thr Tyr His Asn Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 53
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 53

Asp Cys Thr Tyr Arg Asn Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 54
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 54

Asp Cys Thr Tyr Ser Asn Gly Asn Leu Val Trp Cys Thr
1 5 10

<210> 55
<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 55

Asp	Cys	Thr	Tyr	Thr	Arg	Gly	Asn	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 56

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 56

Asp	Cys	Thr	Tyr	Thr	Asn	Gly	Glu	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 57

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 57

Asp	Cys	Thr	Tyr	Thr	Asn	Gly	Arg	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 58

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 58

Asp	Cys	Thr	Tyr	Thr	Asn	Gly	Asp	Leu	Val	Trp	Cys	Thr
1				5					10			

<210> 59
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgG-BP

<400> 59

Asp	Cys	Thr	Tyr	Thr	Asn	Gly	Asn	Leu	Ile	Trp	Cys	Thr
1				5					10			

<210> 60
 <211> 35
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgG-BP

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> X is G, A, V, L, I, M, P, F, W, K, Orn, C, D, E, beta-Ala,
 2-Aminosuberic acid, Diaminopropionic acid, or None

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> X is F, K, Orn, C, D, E, 2-Aminosuberic acid, Diaminopropionic
 acid, or Acetyl-K(K, Orn, C, D, E, 2-Aminosuberic acid,
 Diaminopropionic acid, or Acetyl-K are selectable only when 1st X
 is None)

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> X is C or Q

<220>
 <221> MISC_FEATURE
 <222> (27)..(27)
 <223> X is R, H, D, E, S, T, N, Q, Y, or C

<220>
 <221> MISC_FEATURE
 <222> (29)..(29)

<223> X is R, H, D, E, S, T, N, Q, Y, or C

<220>

<221> MISC_FEATURE

<222> (35)..(35)

<223> X is C, P, or None

<400> 60

Xaa	Xaa	Asn	Met	Gln	Xaa	Gln	Arg	Arg	Phe	Tyr	Glu	Ala	Leu	His	Asp
1				5					10					15	

Pro	Asn	Leu	Asn	Glu	Glu	Gln	Arg	Asn	Ala	Xaa	Ile	Xaa	Ser	Ile	Arg
			20					25					30		

Asp	Asp	Xaa
		35

<210> 61

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X is G, A, V, L, I, M, P, F, W, K, Orn, C, D, E, beta-Ala, 2-Aminosuberic acid, Diaminopropionic acid, or None

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X is F, K, Orn, C, D, E, 2-Aminosuberic acid, Diaminopropionic acid, or Acetyl-K(K, Orn, C, D, E, 2-Aminosuberic acid, Diaminopropionic acid, or Acetyl-K are selectable only when 1st X is None)

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> X is C or Q

<220>

<221> MISC_FEATURE
 <222> (8)..(8)
 <223> X is R, C, K, or K(Z) (Z is a functional group)

 <220>
 <221> MISC_FEATURE
 <222> (27)..(27)
 <223> X is R, H, D, E, S, T, N, Q, Y, C, or K(Z) (Z is a functional group)

 <220>
 <221> MISC_FEATURE
 <222> (29)..(29)
 <223> X is R, H, D, E, S, T, N, Q, Y, C, or K(Z) (Z is a functional group)

 <220>
 <221> MISC_FEATURE
 <222> (35)..(35)
 <223> X is C, P, or None

<400> 61

Xaa	Xaa	Asn	Met	Gln	Xaa	Gln	Xaa	Arg	Phe	Tyr	Glu	Ala	Leu	His	Asp
1				5					10					15	

Pro	Asn	Leu	Asn	Glu	Glu	Gln	Arg	Asn	Ala	Xaa	Ile	Xaa	Ser	Ile	Arg
			20					25					30		

Asp	Asp	Xaa
		35

<210> 62
 <211> 34
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> IgG-BP

<400> 62

Phe	Asn	Met	Gln	Cys	Gln	Arg	Arg	Phe	Tyr	Glu	Ala	Leu	His	Asp	Pro
1				5					10					15	

Asn	Leu	Asn	Glu	Glu	Gln	Arg	Asn	Ala	Arg	Ile	Arg	Ser	Ile	Arg	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

20

25

30

Asp Cys

<210> 63

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 63

Gly	Phe	Asn	Met	Gln	Cys	Gln	Arg	Arg	Phe	Tyr	Glu	Ala	Leu	His	Asp
1				5					10					15	

Pro	Asn	Leu	Asn	Glu	Glu	Gln	Arg	Asn	Ala	Arg	Ile	Arg	Ser	Ile	Arg
			20					25					30		

Asp Asp Cys
35

<210> 64

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 64

Lys	Asn	Met	Gln	Cys	Gln	Arg	Arg	Phe	Tyr	Glu	Ala	Leu	His	Asp	Pro
1				5					10					15	

Asn	Leu	Asn	Glu	Glu	Gln	Arg	Asn	Ala	Arg	Ile	Arg	Ser	Ile	Arg	Asp
			20					25					30		

Asp Cys

<210> 65
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 65

Gly Phe Asn Met Gln Cys Gln Lys Arg Phe Tyr Glu Ala Leu His Asp
1 5 10 15

Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Arg Ile Arg Ser Ile Arg
20 25 30

Asp Asp Cys
35

<210> 66
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG-BP

<400> 66

Lys Asn Met Gln Cys Gln Lys Arg Phe Tyr Glu Ala Leu His Asp Pro
1 5 10 15

Asn Leu Asn Glu Glu Gln Arg Asn Ala Arg Ile Arg Ser Ile Arg Asp
20 25 30

Asp Cys

<210> 67
<211> 33
<212> PRT
<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 67

Phe Asn Met Gln Gln Gln Arg Arg Phe Tyr Glu Ala Leu His Asp Pro
1 5 10 15

Asn Leu Asn Glu Glu Gln Arg Asn Ala Arg Ile Arg Ser Ile Arg Asp
20 25 30

Asp

<210> 68

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 68

Gly Lys Asn Met Gln Cys Gln Arg Arg Phe Tyr Glu Ala Leu His Asp
1 5 10 15

Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Arg Ile Arg Ser Ile Arg
20 25 30

Asp Asp Cys
35

<210> 69

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> K is modified with succinimidyl glutaryl group

<400> 69

Glu Glu Gly Pro Asp Cys Ala Tyr His Lys Gly Glu Leu Val Trp Cys
1 5 10 15

Thr Phe His

<210> 70

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 70

Gly Ser Gly Gly Ser Asp Cys Ala Tyr His Arg Gly Glu Leu Val Trp
1 5 10 15

Cys

<210> 71

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 71

Phe Asn Met Gln Gln Gln Arg Arg Phe Tyr Glu Ala Leu His Asp Pro
1 5 10 15

Asn Leu Asn Glu Glu Gln Arg Asn Ala Arg Ile Arg Ser Ile Arg Asp
20 25 30

Asp Pro Ser Gly Ser Gly Ser Lys

35

40

<210> 72

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> IgG-BP

<400> 72

Arg	Arg	Asp	Cys	Ala	Tyr	His	Lys	Gly	Glu	Leu	Val	Trp	Cys	Thr
1				5					10					15